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   Honvan-Tablet (Diaethyl-dioxystilben-diphosphat) has been administered on 6 patients 
with prostatic cancer. The drug was found to be markedly effective on 3 cases, effective 
on 2 cases, and not effective on 1 case. 
   Even though the period of administration of the drug was too short in the first and 
second cases to improve the subjective symptoms and the physical findings of the pro-
state, marked decrease in total serum acid phosphatase, especially prostatic serum acid 
phosphatase was found in blood biochemical test. Furthermore, marked improvement in 
cystometric findings in the first case was obtained. Therefore, the authors judged the 
drug was effective in both the first and second cases. 
   In the third through fifth cases, the administration of the drug was accompanied by 
castration. The effect of the drug was clinically significant because of loss of subjective 
symptoms, decrease in consistency of the prostate in the fourth and fifth cases, and 
histological improvement of the prostate in the fifth case. 
   In the sixth case simple prostatectomy was performed due to hypertrophied prostate. 
The prostate was turned out to be cancer according to histological study on the speci-
men. Castration was immediately  performed, which was followed by administration of 
the drug. However, only small dosis could be administered because of its side effects. 
Although histological improvement in a part of the prostate was consequently found, 
increase in consistency of the prostate with bone metastasis and increase in total serum 
acid phosphatase were resulted. The authors judged the drug was not effective in this 
case. 
   No side effects of the drug was noticed except compressive feeling of the chest in 
the second :nd fifth cases. Papilar pigmentation was noticed 12-15 days after the begin-
ning of administration of the drug in all cases.
緒 言
前立腺癌 に対 して,抗 男性 ホルモ ン療法 の効
果あることは現在周知 の事実 であ る.数 多 くの
Oestrogen製剤 のうち,Druekrey等(1952)
の合成に よるHonvan(Diaethy1-dioxysti1一
be11-diphosphat)が優れ た効果 を発揮 してお
り,そ れ に就 ては 内外 に多数の報 告があ り,i著
者等 もさきに発表 した ところで ある.Honvan
使用法 としては,Klosterhalfenにょれば,
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Honva且錠 を用 いるのが よい とされている.著
者等は最初 よりHonvan錠 投与療法 を行 い,
み るべ き効果を得たので ここに報告 す る.
Honvan1錠 中にはDiaethy1-dioxysti1-
ben-diphosphat100mgを含有す る.


























































































































治療経過:去 勢術を施行し,ホ ンバン錠(1日 量6
錠)を 投与した.50日閥投与中,血 尿はなかつたが,
前立腺は触診にて不変であつた.8カ 月後,前 立腺は
































日量6錠)を 投与 した.投与後5日 目に胸内苦悶感を




















使用して,著効3例,有 効2例,無 効1例 の臨
床効果を得た.
即ち,第1,2例 は本剤投与期間が短 くて,
自覚症状,前 立腺触診処見の改善は得 られ て
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第1'図a
〔第1例 〕T.T.71才,前 立 腺癌.合 併症=外 傷 後尿 道 狭 窄,糖 尿 病,動 脈 硬 化 症.
ホ ンバ ソ錠 使用 前 の緊 張 減 退膀 胱 を 示 す(Milam-LebermanのRecord-
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第2図b
〔第6例 〕 ホンパン投与後の組織像
